19.66

0.30% -0.06

After Hours: 19.01 -0.65 -3.31%

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $19.66, with a volume of 926.84K. It is down -0.30% in the last 24 hours and up +16.33% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Previous Close:

$19.72

Open:

$19.72

24h Volume:

926.84K

Relative Volume:

0.46

Market Cap:

$3.00B

Revenue:

$205.22M

Net Income/Loss:

$-121.24M

P/E Ratio:

-24.15

EPS:

-0.8141

Net Cash Flow:

$-82.81M

1W Performance:

+5.64%

1M Performance:

+16.33%

6M Performance:

+114.86%

1Y Performance:

+243.11%

1-Day Range:

$19.25

$19.72

1-Week Range:

$18.40

$20.76

52-Week Range:

$5.69

$20.76

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1139)

Industry

Biotechnology (638)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

619

Twitter

@adaptivebiotech

Next Earnings Date

2025-02-11

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	19.66	3.01B	205.22M	-121.24M	-82.81M	-0.8141
VRTX Vertex Pharmaceuticals Inc	433.61	109.65B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.19	82.46B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	451.23	58.81B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	911.98	56.50B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	207.77	43.62B	447.02M	-1.18B	-906.14M	-6.1812

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-25	Initiated	Guggenheim	Buy
Jun-18-25	Initiated	Craig Hallum	Buy
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Nov 26, 2025

Street Watch: Why Adaptive Biotechnologies Corporation stock remains undervaluedGlobal Markets & Weekly High Return Opportunities - BỘ NỘI VỤ

Nov 26, 2025

Its Stock Has Paid Off Big Time For Adaptive Biotechnologies Corp - Setenews

Nov 26, 2025

Nov 25, 2025

Sharon Benzeno Sells 308,477 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat

Nov 25, 2025

Nov 24, 2025

Adaptive Biotechnologies’ Benzeno sells $10.1m in shares By Investing.com - Investing.com Nigeria

Nov 24, 2025

Adaptive Biotechnologies' clonoSEQ® Test Featured in 89 Abstracts at ASH Annual Meeting 2025 - Quiver Quantitative

Nov 24, 2025

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting - Yahoo Finance

Nov 24, 2025

Nov 22, 2025

Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why - Finviz

Nov 22, 2025

Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here’s Why - Insider Monkey

Nov 22, 2025

568,090 Shares in Adaptive Biotechnologies Corporation $ADPT Acquired by Hillsdale Investment Management Inc. - MarketBeat

Nov 22, 2025

Nov 21, 2025

Adaptive Biotechnologies stock hits 52-week high at $17.89 By Investing.com - Investing.com Nigeria

Nov 21, 2025

Officer Benzeno Files To Sell 308,837 Of Adaptive Biotechnologies Corp [ADPT] - TradingView

Nov 21, 2025

ADPT Stock Sees Significant 11.3% Increase - GuruFocus

Nov 21, 2025

Adaptive Biotechnologies stock hits 52-week high at $17.89 - Investing.com

Nov 21, 2025

Check out these key findings about Adaptive Biotechnologies Corp (ADPT) - Setenews

Nov 21, 2025

Why Adaptive Biotechnologies Corporation (1HM) stock stays resilientWeekly Investment Report & Precise Swing Trade Entry Alerts - newser.com

Nov 21, 2025

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Nov 21, 2025

Nov 20, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 6.3%Should You Buy? - MarketBeat

Nov 20, 2025

Is Adaptive Biotechnologies Corporation (1HM) stock a top hedge fund pickAnalyst Upgrade & Weekly High Return Forecasts - newser.com

Nov 20, 2025

Nov 19, 2025